GUBamy
GUB014295 (GUBamy), long-acting amylin analogue
Written by Aaron CuhaReviewed Sep 2026
Also known as: GUB014295
A long-acting amylin analogue from Gubra with one completed phase 1 trial of 76 people sponsored by AbbVie. No result from that trial, and no other human or animal data, has been published; PubMed holds zero records for the compound. Weight loss figures circulating for it could not be traced to any primary source.
Overview
GUB014295, referred to as GUBamy in its originator's communications, is a long-acting analogue of amylin, the pancreatic hormone co-secreted with insulin that slows gastric emptying, suppresses glucagon and promotes satiety. It was discovered by the Danish company Gubra. The one registered clinical trial lists AbbVie as lead sponsor. It belongs to the same class as cagrilintide, petrelintide and eloralintide, all of which now have published human data. GUBamy does not.
What exists is a single registry record. NCT06144684 is a two-part, single-centre, randomised, double-blind, placebo-controlled first-in-human study conducted in the United Kingdom: single ascending doses in lean to overweight or obese but otherwise healthy men, then multiple ascending doses in men and women. It began on 29 November 2023, completed on 5 January 2026 with 76 participants enrolled, and its primary outcomes are safety measures: adverse event incidence, vital signs and laboratory values. Pharmacokinetics and pharmacodynamics are secondary. No results have been posted on the registry. A PubMed search for GUBamy or GUB014295 on 11 September 2026 returned no records at all, and none of three 2026 reviews of the amylin drug class names it in its abstract.
The honest content of this page is therefore short: the mechanism of the class, the sponsor, one completed 76 person phase 1 with safety endpoints, and the statement that no efficacy data of any kind have been published. Weight loss percentages attributed to GUBamy appear on some commercial peptide websites. They could not be traced to any trial record, publication, conference abstract or regulatory document and they are not reproduced here.
Mechanism of action
Amylin acts on receptors formed by the calcitonin receptor paired with receptor activity modifying proteins, in the hindbrain area postrema and elsewhere, to slow gastric emptying, suppress post-meal glucagon secretion and reduce food intake by promoting meal termination. Native amylin aggregates and lasts minutes; long-acting analogues are engineered to resist aggregation and to bind albumin or carry a lipid chain so that they can be dosed weekly. Some agents in the class are selective for amylin receptors and others also activate the calcitonin receptor directly; which GUB014295 is has not been stated in any primary source located for this profile, so it is described only as its trial record describes it, a long-acting amylin analogue. Nothing specific to GUB014295's mechanism, receptor pharmacology, half-life or pharmacodynamics in people or animals has been published.
Human evidence
One completed phase 1 safety study in 76 healthy, overweight or obese volunteers, sponsored by AbbVie, with no results posted or published. No human efficacy data exist in any public source.
- NCT06144684: 76 participants, randomised, double-blind, placebo-controlled, single and multiple ascending doses, completed January 2026. Primary outcomes safety only. Results not posted.
What this does not tell you: Nothing can be said about efficacy, tolerability, dose, half-life or weight effect in people, because nothing has been reported. A phase 1 trial with safety primary endpoints was not designed to demonstrate weight loss even if its data were public. Any specific number attached to GUBamy in circulation is unsourced.
Reading the research record
GUBamy's record is thin for an ordinary reason: it is early. A first-in-human study completed in January 2026 and results from such studies typically appear at conferences and in journals over the following one to two years, if the sponsor chooses to publish. AbbVie's sponsorship of a Gubra compound places it inside a large company's pipeline, where disclosure is governed by commercial timing rather than by scientific completion.
The reason this page exists despite the empty record is the numbers that circulate without it. Commercial peptide websites attach weight loss percentages to GUBamy. The research for this profile checked PubMed, ClinicalTrials.gov and three 2026 class reviews that surveyed press releases and congress abstracts, and found no source for any such figure. Until a trial result is posted or published, the correct statement about GUBamy's efficacy is that none has been reported, and a reader who encounters a percentage should ask where it came from.
The evidence, charted
Fig. 1 · evidence composition
1of 4 citations (25%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2026
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
Phase 1, randomised, double-blind, placebo-controlled, single then multiple ascending subcutaneous doses, single centre, United Kingdom. Lead sponsor AbbVie. Started 29 November 2023, completed 5 January 2026, 76 participants. Primary outcomes: adverse event incidence, vital signs, safety laboratory values. The record describes GUB014295 as a long-acting amylin analogue. No results posted.
ClinicalTrials.gov - Review2026
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
Class review covering pramlintide, cagrilintide, CagriSema, amycretin, eloralintide, petrelintide, Met-233 and AZD6234. Its abstract does not mention GUB014295 or GUBamy.
Peptides - Review2026
Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
Class review of long-acting amylin agents (cagrilintide, eloralintide, petrelintide, NN1213) and the distinction between selective amylin receptor agonists and dual amylin and calcitonin receptor agonists in relation to nausea and tolerability. Its abstract does not mention GUB014295.
Pharmacological Research - Review2026
Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials
Narrative review of amylin-based therapies approved or in human development as of 30 April 2026, drawing on publications, registries, press releases and congress abstracts. Its abstract does not mention GUB014295 or GUBamy by name.
Diabetes, Obesity and Metabolism
Frequently asked questions
What is GUBamy?
GUB014295, a long-acting amylin analogue discovered by Gubra, in the same class as cagrilintide and petrelintide. Its one clinical trial, a phase 1 in 76 volunteers, lists AbbVie as sponsor. It is investigational and not approved anywhere.
How much weight loss does it produce?
No published or posted result answers that. The only trial completed in January 2026 with safety as its primary outcome and has posted no results. Percentages attributed to GUBamy on commercial websites could not be traced to any trial record, publication, abstract or regulatory document.
Is there any published research on it?
Not under either name. A PubMed search for GUBamy or GUB014295 on 11 September 2026 returned zero records, and none of three 2026 reviews of the amylin drug class names it in its abstract. The ClinicalTrials.gov record is the only primary source.